Shares of Tandem Diabetes Care (NASDAQ: TNDM) surged 10.21% in Thursday's trading session following the release of the company's impressive first-quarter 2025 financial results. The medical device company, which specializes in insulin delivery systems, reported revenue that significantly exceeded Wall Street expectations and demonstrated strong growth across its markets.

Tandem Diabetes Care announced Q1 revenue of $234.42 million, representing a 22.3% year-over-year increase and handily beating the analyst consensus estimate of $220.20 million. The company's performance was driven by robust sales growth both in the United States and international markets. U.S. pump sales grew 17% year-over-year, while sales outside the United States saw an impressive 35% increase.

Despite reporting a GAAP loss per share of $1.97, which was wider than expected, investors focused on the company's strong top-line performance and improved operational metrics. Tandem Diabetes Care reported an adjusted EBITDA margin of -2%, a significant improvement from -7% in the same quarter last year. Additionally, the company reaffirmed its full-year 2025 revenue guidance of $997 million to $1.007 billion, aligning closely with analysts' expectations.

John Sheridan, President and CEO of Tandem Diabetes Care, commented on the results, stating, "The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States. We are creating new possibilities for people living with diabetes, while delivering record results that align with our 2025 and long-term financial goals for sustained, double-digit sales growth and profitability."

The market's enthusiastic response to Tandem Diabetes Care's earnings report reflects growing confidence in the company's ability to capitalize on the expanding diabetes care market and improve its financial performance. As the company continues to innovate and expand its reach globally, investors appear optimistic about its long-term growth prospects in the rapidly evolving medical device industry.